Amgen registers Phase 4 trial testing Repatha's effect on coronary plaque burden
New Amgen-sponsored study will compare evolocumab plus routine lipid management against lipid management alone in patients with early coronary plaque.
Amgen posted one new trial registration this week focused on cardiovascular imaging outcomes.
- Amgen registered a Phase 4 trial (NCT07803679) testing Evolocumab plus routine lipid management against routine lipid management alone in modifying non-calcified plaque volume as measured by AI-enabled Quantitative Coronary Plaque Analysis from Coronary Computed Tomography Angiography, in patients with subclinical atheroma.1 The study is not yet recruiting, with an estimated enrollment of 308 participants1 and a primary endpoint of change in non-calcified plaque volume from baseline to Week 721. Estimated start is January 2027 with primary completion expected April 2029, per the registry.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.